News

Healthtech Startup Avammune Bags $12 Mn From Capital 2B, Others

Publications

AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model.
Avijit Goswami, Barnali Deb, Sandeep Goyal, Abhishek Gosavi, Mukund Mali, Ashwita M. Martis, Princy Khurana, Mukesh Gangar, Digambar Raykar, Ankita Mohanty and Aditya Kulkarni

Molecules. October 2022, 27, 6721

Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy.
Mukesh Gangar, Sandeep Goyal, Digambar Raykar, Princy Khurana, Ashwita M. Martis, Avijit Goswami, Ishani Ghoshal, Ketul V. Patel, Yadav Nagare, Santosh Raikar, Apurba Mukherjee, Rajath Cyriac, Jean-François Paquin, Aditya Kulkarni

Bioorganic Chemistry. December 2021, 0045-2068/© 2021 Elsevier Inc.

Conference Abstracts

Abstract 4484: Discovery of a potential first-in-class Za targeted small molecule inhibitor of ADAR1 p150 which demonstrates strong anti-tumor efficacy
Avijit Goswami, Sandeep Goyal, Kawaljit Singh, Princy Khurana, Barnali Deb, Aditya Kulkarni

Journal: Cancer Research Cancer Res (2024) 84 (6_Supplement): 4484. https://doi.org/10.1158/1538-7445.AM2024-4484

864 AVA-NP-695, a potent and selective ENPP1 inhibitor, demonstrates strong anti-tumor efficacy as monotherapy and in combination with radiation
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Ishani Ghoshal, Aditya Kulkarni

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A963; DOI:10.1136/jitc-2023-SITC2023.0864

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics